You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


ICR cancer drug NXP800 to enter Phase I trials

An investigational drug called NXP800, discovered at the Cancer Research UK Cancer Therapeutics Unit at London’s Institute of Cancer Research (ICR), is to enter Phase I clinical trials in patients with advanced cancers.